Approximately 30,000–40,000 people die from liver disease each year, according to the American Liver Foundation.
“Although the artificial liver is not yet cleared for use on humans, these findings show promise as an effective treatment option for diseases like liver cancer and hepatitis, which is becoming an increasingly common diagnosis.”
For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant.
Developed by Scott Nyberg, M.D., Ph.D., principal investigator in the Artificial Liver and Liver Transplantation Laboratory at Mayo Clinic and liver transplant surgeon, the device uses healthy hepatocytes, or liver cells, from pigs to do the job of a normal, healthy liver, which aids in digestion and the removal of waste and toxins from the bloodstream. Treatment with the Spheroid Reservoir Bioartificial Liver (SRBAL) has been shown to reduce the severity of liver disease and improve survival in pigs. Future clinical studies are planned to assess the SRBAL as a less-invasive, long-term treatment option to liver transplantation. Results from a study using the device in a pivotal preclinical trial were published today in the Journal of Hepatology.
“Acute liver failure claims the lives of over 30 percent of people who are diagnosed with this condition. Liver transplantation has been the go-to option for treating acute liver failure, but it also comes with many risks and isn’t always an option, due to compatibility and availability of donor livers,” says Dr. Nyberg. “A bioartificial liver device could allow physicians to treat and extend the lives of more patients, safely and cost-effectively, with fewer risks.”
The study conducted by Dr. Nyberg was designed to serve as a preclinical trial on pigs with drug-induced acute liver failure. The animals were treated using the Spheroid Reservoir Bioartificial Liver and were injected with healthy donor hepatocytes to determine if this treatment method could reverse the severity of their disease.
“This study demonstrated that animals treated using the bioartificial liver responded to the healthy hepatocytes and reached the study endpoint with less disease severity than animals that received other forms of treatment,” said Dr. Nyberg. “Although the artificial liver is not yet cleared for use on humans, these findings show promise as an effective treatment option for diseases like liver cancer and hepatitis, which is becoming an increasingly common diagnosis.”
The Latest on: Bioartificial Liver
via Google News
The Latest on: Bioartificial Liver
- Annals of Surgeryon August 19, 2021 at 5:00 pm
May 11, 2004 Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure The first prospective, randomized, controlled, multicenter trial ...
- PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Ruleson August 19, 2021 at 4:24 am
When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy prodrug ifosfamide at the site of the cancer.
- PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Ruleson August 19, 2021 at 4:20 am
When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy prodrug ifosfamide at the site of the ...
- PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focuson August 16, 2021 at 7:01 am
NASDAQ #BigBoardStock--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature ...
- PharmaCyte Biotech Announces Closing of $15-Million Public Offeringon August 12, 2021 at 12:14 pm
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation ...
- Study & Researchon August 11, 2021 at 5:00 pm
This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for the patients ...
- Shapiro on Transplantationon August 2, 2021 at 5:00 pm
Experts And Viewpoints, February 24, 2009 Cryopreserved Agarose-Encapsulated Islets and the Future of Bioartificial In ... 2009 Kidney Allocation in Liver Transplant Candidates With Renal Failure ...
- A Bioartificial System Acts as "Dialysis" For Failing Livers in Pigs (2 of 2) (IMAGE)on August 2, 2021 at 6:05 am
A microscopic image of the carriers used to culture liver progenitor-like cells in the bioartificial liver. This material relates to a paper that appeared in the Jul. 8, 2020, issue of < ...
- Acute Liver Failureon July 31, 2021 at 10:05 pm
Figure 1. Figure 1. Clinical Features of Acute Liver Failure. Acute liver failure is a rare but life-threatening critical illness that occurs most often in patients who do not have preexisting ...
- IIT Delhi And ILBS Tie Up To Solve Challenges In Medical Practice And Health Serviceson September 26, 2020 at 9:52 am
bio-sensor development; computational biology and big data; material sciences, liver dialysis membranes and machines and 3D bio-printing and bio-artificial liver.
via Bing News